KRd vs VRd for initial therapy of newly diagnosed multiple myeloma
Dr Shaji Kumar - Mayo Clinic, Rochester, USA
1 Jun 2020
Teclistamab for patients with heavily pretreated relapsed or refractory multiple...
Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA
1 Jun 2020
Denosumab in multiple myeloma patients with renal insufficiency
Dr Elizabeth O'Donnell - Massachusetts General Hospital, Boston, USA
30 May 2020
CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell th...
Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA
29 May 2020
Managing Hodgkin lymphoma during the COVID-19 outbreak
Dr Anna Sureda - Hospitalet de Llobregat, Barcelona, Spain
20 Apr 2020
Managing multiple myeloma during the COVID-19 outbreak
Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA
17 Apr 2020
Managing Hodgkin lymphoma in a COVID-19 world
Prof Andreas Engert - University Hospital of Cologne, Cologne, Germany
17 Apr 2020
Immune checkpoint based approaches in AML and MDS
Dr Naval Daver - University of Texas MD Anderson Cancer Center, Houston, USA
8 Apr 2020
CARTs for the treatment of T-cell malignancies
Dr John DiPersio - Siteman Cancer Center, St. Louis, USA
1 Apr 2020
Treating haematological cancers in Romania
Dr Ciprian Tomuleasa - Ion Chiricuta Clinical Research Center, Cluj Napoca, Rom...
10 Mar 2020
The landscape of haematological cancers in India
Dr Hemant Malhotra - Mahatma Gandhi Medical College Hospital, Jaipur, India
10 Mar 2020
Haematological malignancies: Latest advances from ASH 2019
Dr Eloísa Riva - Hospital de Clínicas, Montevideo, Uruguay
10 Mar 2020
